Financials data is unavailable for this security.
View more
Year on year Standard Chem & Pharm Co Ltd had little change in net income (from 815.41m to 834.89m) despite revenues that grew 6.64% from 5.85bn to 6.24bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 19.00% to 19.15%.
| Gross margin | 43.86% |
|---|---|
| Net profit margin | 18.20% |
| Operating margin | 20.29% |
| Return on assets | 10.47% |
|---|---|
| Return on equity | 16.07% |
| Return on investment | 20.28% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at Standard Chem & Pharm Co Ltd fell by 222.64m. However, the company earned 1.34bn from its operations for a Cash Flow Margin of 21.42%. In addition the company used 485.51m on investing activities and also paid 1.08bn in financing cash flows.
| Cash flow per share | 8.83 |
|---|---|
| Price/Cash flow per share | 7.36 |
| Book value per share | 32.57 |
|---|---|
| Tangible book value per share | 31.40 |
More ▼
Balance sheet in TWDView more
| Current ratio | 2.16 |
|---|---|
| Quick ratio | 1.49 |
| Total debt/total equity | 0.1395 |
|---|---|
| Total debt/total capital | 0.0856 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.00% and 2.39%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 4.64% |
|---|---|
| Div growth rate (5 year) | 12.47% |
| Payout ratio (TTM) | 56.49% |
| EPS growth(5 years) | 17.40 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -0.9955 |
More ▼
